PK, PD AND SAFETY OF FIRST-IN-HUMAN, FIRST-IN-CLASS PHASE I TRIAL (AUR103-101; BHARAT) OF AUR103, AN ORAL CD47 INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES

AUR103 - Dr. Reddy’s

Venclexta (venetoclax) - Roche, AbbVie, Walter and Eliza Hall Institute

azacitidine - Generic mfg.

https://library.ehaweb.org/eha/2023/eha2023-congress/386569/akhil.kumar.pk.pd.and.safety.of.first-in-human.first-in-class.phase.i.trial.html?f=menu%3D16%2Abrowseby%3D8%2Asortby%3D2%2Ace_id%3D2489%2Aot_id%3D27918%2Atrend%3D4016%2Amarker%3D4178

Manjunath Krishnappa; Divyesh Mandavia; Minish Jain; Mukesh S; Ankit Patel; Anshul Agarwal; Sanjeev Giri; Nirbhay Kumar Tiwari; Saravanan Thiyagarajan; Mamon Dey; Gutta Padmanabha Naidu; Murali Ramachandra; Akhil Kumar

May 12, 2023